 |
Too Much of a Good Thing: Clinical Study Sites Struggle to Manage Responses to Ad Campaigns
by WIRB-Copernicus Group
|
|
|
Five Essential Considerations for Efficient Site Contracts and Payments
by Clintrax Global
|
|
|
Envisioning the Site of the Future: Integration of Clinical Research with Clinical Care Driving Change
by CenterWatch
|
|
|
eTMF Adoption and Integration Accelerating: Audit Support; Faster Startup and Remote Oversight Top Motivators
by CenterWatch
|
|
|
Growing Role for AMC Clinical Trial Offices: CTOs Gaining Leverage, Expanding Capabilities, Improving Performance
by CenterWatch
|
|
|
How to Avoid Leaving Money on the Table: Ten Tips for Budgeting, Negotiating, and Collecting Clinical Trial Payments
by PFS Clinical
|
|
|
Millennials Accelerate Seismic Shift in Clinical Operations: New Expectations Set the Stage for Future Research
by CenterWatch
|
|
|
Shifting the Tide of Inefficient Site Contract Negotiations: Turn to an Expert
by WIRB-Copernicus Group
|
|
|
The Need for – and Barriers to – Adopting eSource: New Regulation and Partnership May Finally End Poor Interoperability and the Aversion to Change
by CenterWatch
|
|
|
Solving the Problem of Clinical Research Enrollment
by WIRB-Copernicus Group
|
|
|
Avoid Enrollment Pitfalls: Find Your Best-fit Clinical Trial Sites
by WIRB-Copernicus Group
|
|
|
Six Practices of High Performing Clinical Research Sites
by WIRB-Copernicus Group
|
|
|
Looking Ahead to 2018: Insights into Clinical Research Trends from Our Experts
by WIRB-Copernicus Group
|
|
|
Sites Smothered by Technology Solutions: Investigative Sites Call for Compatibility and Quality
by CenterWatch
|
|
|
Advancing Patient Protection Through Proposed Common Rule Changes for Informed Consent
by CenterWatch
|
|
|
Compensating Participants in Clinical Research: Current thinking
by WIRB-Copernicus Group
|
|
|
…But Is It Gene Therapy?: Debating a (Controversial) Definition
by WIRB-Copernicus Group
|
|
|
Minimizing Impact of New NIH Recombinant DNA Advisory Committee Review Process on Early Phase Human Gene Therapy Studies
by WIRB-Copernicus Group
|
|
|
The Revised NIH Guidelines 2016: Assessing the Impact on Human Gene Transfer Clinical Trials
by WIRB-Copernicus Group
|
|
|
Pragmatic Clinical Trials: What You Need to Know
by WIRB-Copernicus Group
|
|
|
Managing the Unmanageable: Meeting the Challenge of Appropriate Safety Report Distribution
by ePharmaSolutions
|
|
|
Interventional Clinical Trial or Registry Study?: Writing Protocols that Demonstrate the Difference
by WIRB-Copernicus Group
|
|
|
Innovation in Investigator Site Contracting
by Clintrax Global
|
|
|
Gene Therapy and Genomic Editing: Understanding Basic Concepts
by WIRB-Copernicus Group
|
|
|
Investigational Drugs Outside of Clinical Trials: Understanding Expanded Access and Right-to-Try
by WIRB-Copernicus Group
|
|
|
Choosing the Right Solution: Improving the Site Feasibility Process
by WIRB-Copernicus Group
|
|
|
Alphabetical Glossary of Terms - Gene Therapy & Immunotherapy - Revised, Second Edition
by WIRB-Copernicus Group
|
|
|
The eMDR Requirement: Best Practices for Enhancing Collaboration with the FDA
by EtQ
|
|
|
Document Control in GxP Environments
by Solabs
|
|
|
Strategies for Rapid EQMS Deployment
by Pilgrim Quality Solutions
|
|
|
A New Approach to Quality and Compliance eLearning
by UL EduNeering
|
|
|
Tale of Two C's: From Compliance to Competency
by UL EduNeering
|
|
|
Measuring Training Effectiveness: A Benchmarking Study – 2014 Results; 2015 Forecast
by UL EduNeering
|
|
|
The FDA's Focus on Metrics, Performance and Quality
by UL EduNeering
|
|
|
Life Science 2014 Benchmarking Study: Trends and Best Practices Based on Our Work with the US FDA and Over 250 Companies
by UL EduNeering
|
|
|
Cutting Costs, Saving Time: Improving Life Sciences Operations with Digital Signatures
by ARX
|
|
|
DOJ's Laser Focus on GMPs in 2013
by UL EduNeering
|
|
|
FTC v. Actavis: After the Verdict
by Datamonitor
|
|
|
The Pharmaceutical Industry's Transition to Electronic Processes
by MasterControl
|
|
|
ComplianceWire: Life Science 2012/2013 Benchmarking Study
by UL EduNeering
|
|
|
The Saas LMS and Total Cost of Ownership in FDA-regulated Companies
by UL EduNeering
|
|
|
How to Report Suspected False Data to the FDA
by FDAnews
|
